多柔比星联合依沃福沙胺对比多柔比星单药治疗局部晚期、不可切除或转移性软组织肉瘤(TH CR-406/SARC021):一项国际、多中心、开放标签、随机3期试验
这项国际、开放标签、随机3期试验在13个国家81个中心纳入640例局部晚期、不可切除或转移性中高级别软组织肉瘤患者,随机接受多柔比星联合依沃福沙胺或多柔比星单药一线治疗。联合组与单药组中位总生存期分别为18.4个月和19.0个月(HR 1.06,95%CI 0.88-1.29;P=0.527),联合组3级及以上血液学不良事件和严重不良事件更多;作者结论为联合依沃福沙胺未能改善总生存,不推荐该联合方案用于此适应症。
要点
- 多柔比星联合依沃福沙胺对比多柔比星单药一线治疗晚期软组织肉瘤,中位总生存期18.4个月 vs 19.0个月(HR 1.06,95%CI 0.88-1.29;P=0.527)。
- 联合组3级及以上贫血发生率48%(150/313)高于单药组21%(65/308),3-4级血小板减少14%(45/313)高于1%(4/308)。
- 联合组严重不良事件46%(145/313)高于单药组32%(99/308),治疗相关死亡联合组5例(2%)vs 单药组1例(<1%)。
核心结论
- 在局部晚期、不可切除或转移性软组织肉瘤患者中,多柔比星联合依沃福沙胺一线治疗对比多柔比星单药未改善总生存,因此不推荐该联合方案用于此适应症。
研究设计与样本
- 国际、开放标签、随机3期多中心试验(TH CR-406/SARC021),在13个国家81个学术或社区研究中心开展。
- 纳入年龄15岁及以上、组织学诊断为中级别或高级别、无标准治愈性治疗可用的晚期不可切除或转移性软组织肉瘤患者,ECOG体能状态0-1,按RECIST 1.1有可测量病灶。
- 共640例患者按1:1随机分配至多柔比星联合依沃福沙胺组(317例)或多柔比星单药组(323例),全部纳入意向治疗分析。
- 多柔比星75 mg/m2(弹丸注射5-20分钟或持续静脉输注6-96小时,每21天周期第1天,最多6周期);依沃福沙胺300 mg/m2静脉输注30-60分钟,每21天周期第1天和第8天,最多6周期。
- 主要终点为意向治疗人群的总生存期;安全性分析纳入所有接受任意剂量研究药物的患者。
主要发现
- 总生存期终点未达到:风险比1.06(95%CI 0.88-1.29;P=0.527)。
- 中位总生存期联合组18.4个月(95%CI 15.6-22.1)vs 单药组19.0个月(95%CI 16.2-22.4)。
- 3级及以上贫血联合组150/313(48%)vs 单药组65/308(21%);中性粒细胞减少联合组47/313(15%)vs 单药组92/308(30%)。
- 3级及以上发热性中性粒细胞减少联合组57/313(18%)vs 单药组34/308(11%);白细胞减少联合组22/313(7%)vs 单药组17/308(6%)。
- 3-4级血小板减少联合组45/313(14%)vs 单药组4/308(1%);3-4级口腔炎联合组26/313(8%)vs 单药组7/308(2%);严重不良事件联合组145/313(46%)vs 单药组99/308(32%)。
关键数值与推荐
- 联合组治疗相关死亡5/313(2%):脓毒症2例、感染性休克1例、充血性心力衰竭1例、原因不明1例;单药组治疗相关死亡1/308(<1%):乳酸酸中毒1例。
临床怎么用
- 作者结论为多柔比星联合依沃福沙胺对比多柔比星单药未改善总生存,因此不推荐该联合方案用于局部晚期、不可切除或转移性软组织肉瘤的一线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evofosfamide is a hypoxia-activated prodrug of bromo-isophosphoramide mustard. We aimed to assess the benefit of adding evofosfamide to doxorubicin as first-line therapy for advanced soft-tissue sarcomas. METHODS: We did this international, open-label, randomised, phase 3, multicentre trial (TH CR-406/SARC021) at 81 academic or community investigational sites in 13 countries. Eligible patients were aged 15 years or older with a diagnosis of an advanced unresectable or metastatic soft-tissue sarcoma, of intermediate or high grade, for which no standard curative therapy was available, an Eastern Cooperative Oncology Group performance status of 0-1, and measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1. Patients were randomly assigned (1:1) to receive doxorubicin alone (75 mg/m2 via bolus injection administered over 5-20 min or continuous intravenous infusion for 6-96 h on day 1 of every 21-day cycle for up to six cycles) or doxorubicin (given via the same dose procedure) plus evofosfamide (300 mg/m2 intravenously for 30-60 min on days 1 and 8 of every 21-day cycle for up to six cycles). After six cycles of treatment, patients in the single-drug doxorubicin group were followed up expectantly whereas patients with stable or responsive disease in the combination group were allowed to continue with evofosfamide monotherapy until documented disease progression. A web-based central randomisation with block sizes of two and four was stratified by extent of disease, doxorubicin administration method, and previous systemic therapy. Patients and investigators were not masked to treatment assignment. The primary endpoint was overall survival, analysed in the intention-to-treat population. Safety analyses were done in all patients who received any amount of study drug. This study was registered with ClinicalTrials.gov, number NCT01440088. FINDINGS: Between Sept 26, 2011, and Jan 22, 2014, 640 patients were enrolled and randomly assigned to a treatment group (317 to doxorubicin plus evofosfamide and 323 to doxorubicin alone), all of whom were included in the intention-to-treat analysis. The overall survival endpoint was not reached (hazard ratio 1·06, 95% CI 0·88-1·29; p=0·527), with a median overall survival of 18·4 months (95% CI 15·6-22·1) with doxorubicin plus evofosfamide versus 19·0 months (16·2-22·4) with doxorubicin alone. The most common grade 3 or worse adverse events in both groups were haematological, including anaemia (150 [48%] of 313 patients in the doxorubicin plus evofosfamide group vs 65 [21%] of 308 in the doxorubicin group), neutropenia (47 [15%] vs 92 [30%]), febrile neutropenia (57 [18%] vs 34 [11%]), leucopenia (22 [7%] vs 17 [6%]), decreased neutrophil count (31 [10%] vs 41 [13%]), and decreased white blood cell count (39 [13%] vs 33 [11%]). Grade 3-4 thrombocytopenia was more common in the combination group (45 [14%]) than in the doxorubicin alone group (four [1%]), as was grade 3-4 stomatitis (26 [8%] vs seven [2%]). Serious adverse events were reported in 145 (46%) of 313 patients in the combination group and 99 (32%) of 308 in the doxorubicin alone group. Five (2%) patients died from treatment-related causes in the combination group (sepsis [n=2], septic shock [n=1], congestive cardiac failure [n=1], and unknown cause [n=1]) versus one (<1%) patient in the doxorubicin alone group (lactic acidosis [n=1]). INTERPRETATION: The addition of evofosfamide to doxorubicin as first-line therapy did not improve overall survival compared with single-drug doxorubicin in patients with locally advanced, unresectable, or metastatic soft-tissue sarcomas and so this combination cannot be recommended in this setting. FUNDING: Threshold Pharmaceuticals.
引用
- Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017. PMID: 28651927. doi:10.1016/S1470-2045(17)30381-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。